Vifor Licenses Rare Kidney Disease Drug in Comeback for Travere

Vifor Pharma and Travere Therapeutics inked a collaboration and licensing partnership to commercialize sparsentan in Europe, Australia and New Zealand. The drug is being developed to treat FSGS and IgAN, both rare progressive kidney diseases that are leading causes of end-stage kidney disease. Currently, there are no approved drugs for the two disorders.